Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.

February 25, 2026 updated by: Lacer S.A.

Clinical Study to Evaluate the Efficacy and Safety of a Cosmetic Product in Subjects With Telogen Effluvium and Androgenic Alopecia

The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia (AGA). The main question it aims to answer is:

• Does a shampoo use help to reduce the visible signs of hair loss related to TE and AGA?

Subjects will use the shampoo for 3 months and visit the clinic for the visits established by the protocol.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Madrid
      • Alcalá de Henares, Madrid, Spain, 28805
        • Centro Médico Complutense Grupo Virtus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Clinic database

Description

Inclusion Criteria:

  • Sex: Both (50% women; 50% men).
  • Age: 18-65 years.
  • Subjects with hair loss due to telogen effluvium or mild or incipient androgenic alopecia, in an 80/20 ratio.
  • Degree of androgenic alopecia: Ludwig scale score I-II for women and Hamilton-Norwood scale score III-II for men.
  • Telogen effluvium: Combing test.
  • Subjects with all hair types (oily, combination, sensitive, etc.).
  • Subjects with all scalp types (normal, sensitive, etc.).
  • Agree to participate voluntarily in the study and provide written informed consent.
  • Adequate level of understanding of the clinical study.
  • Good health (physical and mental).
  • Availability to attend visits to the research centres.
  • No application of any product to the experimental area on the first day of the trial.

Exclusion Criteria:

  • Individuals under 18 years of age.
  • Pregnant or breastfeeding women.
  • Injuries or infection in the test area.
  • History of allergies to cosmetic products.
  • Known allergies to product components.
  • Sensitivity to any product component.
  • Patients who have undergone recent surgery or treatments in the study area.
  • Cancer patients.
  • Volunteers currently taking antibiotics, antihistamines, corticosteroids, beta-blockers, retinoids, azelaic acid, or acne therapies, or whose treatment ended within 15 days prior to the start of the study. Participation in another clinical study.
  • Use of or having used cosmetic products and/or oral or topical treatments for hair loss for at least 6 months.
  • Hair cutting or dyeing during the study.
  • Health problems, to be assessed by the specialist, that may compromise adherence to the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
anti-hair loss shampoo
Other: anti-hair loss shampoo
anti-hair loss shampoo use for 3 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in hair lenght and thickness
Time Frame: From baseline to the end of use at 3 months.
From baseline to the end of use at 3 months.

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in hair lenght and thickness at 1 month
Time Frame: Baseline and 1 month of use
Baseline and 1 month of use

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lacer S.A.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2025

Primary Completion (Actual)

October 16, 2025

Study Completion (Actual)

October 16, 2025

Study Registration Dates

First Submitted

February 19, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 25, 2026

Study Record Updates

Last Update Posted (Actual)

February 27, 2026

Last Update Submitted That Met QC Criteria

February 25, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LACER_2406_COS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Only summary of the results to support the publication will be shared. No complete study documents will shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe